We have previously shown that tumor phenotypic evolution during combination ribociclib therapy leads to the emergence of cell cycle reactivation through a shift from estrogen to alternative growth signal-mediated proliferation in this early-stage ER+ breast cancer population10. The gene discussed is ESR1; the disease is breast cancer.